Review Article
Hepatitis C Variability, Patterns of Resistance, and Impact on Therapy
Table 2
Role of IL-28B in HCV treatment.
|
IL-28B SNP | PR (IDEAL) | Telaprevir (advance) | Boceprevir (SPRINT-2) | ITT population | Adherent population | TVR/PR | PR control | BOC/PR* | PR control |
| CC | 69% | 79% | 90% | 64% | 80–82% | 78% | CT | 33% | 38% | 71% | 25% | 65–71% | 28% | TT | 27% | 26% | 73% | 23% | 55–59% | 27% |
|
|
*Includes BOC/RGT and BOC/PR48 arms [61, 69, 80, 81].
|